Effect of norethisterone acetate on markers of inflammation in postmenopausal women receiving estradiol

Gynaecologia et Perinatologia, Supplement

Volumn 14, Issue 1, 2005, Pages 12-17

  Žegura, Branka ^a   Gužič Salobir, Barbara ^b   Keber, Irena ^b   Šebeštjen, Miran ^b   Koenig, Wolfgang ^c  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Hormones; Inflammation

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROFEM; FIBRINOGEN; INTERLEUKIN 6; NORETHISTERONE ACETATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOGEN BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; NORMAL HUMAN; POSTMENOPAUSE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 20744432173     PISSN: 13310151     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 1978; 89: 157-61.
2. Rosenberg L, Hennekens CH, Rosner B et al. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 1981; 139: 47-51.
3. Johansson BW, Kaij L, Kullander S, Lennér S et al. On some late effects of bilateral oophorectomy in the age range 15-30 years. Acta Obstetr Gynecol Scand 1975; 54: 449-61.
4. Lip GYH, Blann AD, Jones AF, Beevers DG. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J 1997; 134: 764-71.
5. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63.
6. Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-61.
7. Mijatovic V, van der Mooren MJ, Stehouwer CDA, et al. Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection. Gynecol Endocrinol 1999; 13: 130-44.
8. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.
9. Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus pregestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
10. The Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's health initiative randomized controlled trial. JAMA 2004; 291: 1701-12.
11. Van Baal WM, Kenemans P, van der Mooren Mj et al. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 1999; 81: 925-8.
12. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100: 713-6.
13. Cushman M, Legault C, Barrett-Connor E. et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the postmenopausal estrogen/progestin interventions (PEPI) study. Circulation 1999; 100: 717-22.
14. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.
15. Koenig W, Sund M, Fröhlich M et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation 1999; 99: 237-42.
16. McKenzie, Jaap AJ, Gallacher et al. Metabolic, inflammatory and haemostatic effects of a low-dose continous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk? Clinical Endocrinol 2003; 59: 682-9.
17. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-43.
18. Liuzzo G, Biasucci L M, Gallimore J R et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina N Engl J Med 1994; 331:417-24.
19. Wakatsuki A, Okatani Y, Ikenoue N et al. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 2002; 105: 1436-9.
20. Zegura B, Keber I, Šebeštjen M, Koenig W. Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis 2003; 168: 123-9.
21. Walsh BW, Cox DA, Sashegyi A et al. Role of tumor necrosis factor-a and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 2001; 88: 825-8.
22. Parkar M, Tabona P, Newman H et al. IL-6 expression by oral fibroblasts is regulated by androgen. Cytokine 1998; 10: 613-9.
23. Chetkowski RJ, Meldrum DR, Steingold KA et al. L.Biologic effects of transdermal estradiol. N engl J Med 1986; 314: 1615-20.
24. Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 β-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 1985; 152: 1099-106.
25. Vehkavaara S, Silveira A, Hakala-Ala Pietilä T et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001; 85: 619-25.
26. Lowe GDO, Upton MN, Rumley A et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein. Thromb Haemost 2001; 86: 550-6.
27. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-Reactive protein levels in overweight and obese adults. JAMA 1999; 282: 2131-5.
28. Yamada T Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 1999; 37: 381-8.
29. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
30. Scarabin P-Y, Alhenc-Gelas M, Plu-Bureau G. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071-8.
31. Lindoff C, Peterson F, Lecander I, Martinsson G, Åstedt B. transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease. Maturitas 1996; 24:43-50.
32. The writing group for the estradiol clotting factors study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential madroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. Thromb Haemost 1996; 3: 476-80.
33. Kroon UB, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994; 71: 420-3.
34. Alkjaersig N, Fletcher AP, de Ziegler D et al. Blood coagulation in postmenopausal women given estrogen treatment: comparison of transdermal and oral administration. J Lab Clin Med 1988; 111: 224-8.